Well it seems that the enthusiasm has been squashed out of the retail shareholders.. A most intriguing pair of announcements.
It would seem that the appointment of a new Lyramid CEO preempts an almost certain spin off. I wouldn't think that Bart would have accepted this opportunity if there wasn't a fair chance of success...as soon as the FDA provide Orphan Drug Designation. Has anyone checked the mailbox ? probably sitting on the bottom of the in-tray and may have the ceremonial "surprise" opening in the very near term.
So what leaves the CEO of Advandgen ? Where does that leave Maria ? Perhaps as new Chair ??
And where does the leave Kinera ? all a bit of a mystery really.
The push to expose value to the shareholders can have no more importance than to that of the CEO ? Is this an exit plan ?
regardless of the plan i think there are a few more ann to come before eofy.
Well it seems that the enthusiasm has been squashed out of the...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1197315 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 109888 | 2 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable